ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 6,364 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $72.10, for a total transaction of $458,844.40. Following the completion of the sale, the insider now directly owns 84,476 shares in the company, valued at $6,090,719.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

David Pendarvis also recently made the following trade(s):

  • On Monday, July 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The stock was sold at an average price of $77.36, for a total transaction of $492,319.04.
  • On Monday, June 5th, David Pendarvis sold 6,365 shares of ResMed stock. The stock was sold at an average price of $72.62, for a total transaction of $462,226.30.

ResMed Inc. (RMD) opened at 75.09 on Friday. The firm’s 50-day moving average is $77.30 and its 200-day moving average is $71.87. The firm has a market capitalization of $10.66 billion, a PE ratio of 31.29 and a beta of 0.83. ResMed Inc. has a 52-week low of $56.59 and a 52-week high of $79.63.

ResMed (NYSE:RMD) last issued its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, topping the consensus estimate of $0.75 by $0.02. The company had revenue of $556.69 million for the quarter, compared to analyst estimates of $557.68 million. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 EPS. On average, analysts anticipate that ResMed Inc. will post $3.05 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be given a dividend of $0.35 per share. This is a positive change from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a dividend yield of 1.86%. The ex-dividend date is Tuesday, August 15th. ResMed’s payout ratio is presently 54.77%.

COPYRIGHT VIOLATION WARNING: “David Pendarvis Sells 6,364 Shares of ResMed Inc. (RMD) Stock” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/06/david-pendarvis-sells-6364-shares-of-resmed-inc-rmd-stock.html.

RMD has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of ResMed from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Thursday, July 6th. Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday. BMO Capital Markets reissued a “hold” rating on shares of ResMed in a report on Friday, May 12th. Finally, Credit Suisse Group downgraded shares of ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday. Four analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $65.63.

Several large investors have recently modified their holdings of RMD. BlackRock Inc. raised its stake in shares of ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after buying an additional 13,094,421 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after buying an additional 508,392 shares during the last quarter. State Street Corp raised its stake in shares of ResMed by 2.1% in the first quarter. State Street Corp now owns 4,598,911 shares of the medical equipment provider’s stock valued at $330,983,000 after buying an additional 95,552 shares during the last quarter. FMR LLC raised its stake in shares of ResMed by 1.9% in the first quarter. FMR LLC now owns 4,010,810 shares of the medical equipment provider’s stock valued at $288,659,000 after buying an additional 74,389 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of ResMed by 1.2% in the second quarter. Bank of New York Mellon Corp now owns 2,266,663 shares of the medical equipment provider’s stock valued at $176,505,000 after buying an additional 25,925 shares during the last quarter. Institutional investors own 60.65% of the company’s stock.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.